Provided by Tiger Trade Technology Pte. Ltd.

HBM HOLDINGS-B

14.190
-0.250-1.73%
Volume:8.78M
Turnover:125.24M
Market Cap:12.33B
PE:129
High:14.740
Open:14.440
Low:13.980
Close:14.440
52wk High:17.070
52wk Low:9.460
Shares:869.00M
HK Float Shares:869.00M
Volume Ratio:0.52
T/O Rate:1.01%
Dividend:- -
Dividend Rate:- -
EPS(LYR):0.110
ROE:23.97%
ROA:10.88%
PB:3.76
PE(LYR):129.00
PS:8.78

Loading ...

HBM Holdings Signals Strong First-Half 2026: Revenue to Rise c.20% to Up to US$125 Million; Profit Seen at US$62-67 Million

Bulletin Express
·
Jul 24

HBM Holdings-B (02142) Expects Mid-Year Net Profit Between $62 Million and $67 Million

Stock News
·
Jul 24

Press Release: Harbour Biomed Announces Positive Profit Alert for 2026 Interim Results, Marking Seventh Consecutive Profitable Half-year as Platform-based Advantages Drive Sustainable Growth

Dow Jones
·
Jul 24

Hbm Holdings - Expects Revenue of Us$120 Mln-us$125 Mln for Six Months Ended 30 June 2026

THOMSON REUTERS
·
Jul 24

Nona Biosciences Enters Research Collaboration with the Medical University of Vienna to Advance Fully Human Antibody Development for Infectious Diseases

THOMSON REUTERS
·
Jul 23

Is HBM Holdings (SEHK:2142) Fully Valued After Its Asthma IND Approval?

Simply Wall St.
·
Jul 21

HBM Holdings's Asthma Drug Candidate Secures China's Approval

MT Newswires Live
·
Jul 16

HBM HOLDINGS-B Receives Regulatory Clearance for Asthma Drug Trial

Stock News
·
Jul 15

China NMPA Clears Kelun-biotech, Harbour Biomed Asthma IND for Skb575/hbm7575

Reuters
·
Jul 15

Hbm Holdings - Hbm7575 Co-developed by Harbour Biomed and Kelun-biotech

THOMSON REUTERS
·
Jul 15

Hbm Holdings - Nmpa Approves Ind Application for Hbm7575 for Asthma

THOMSON REUTERS
·
Jul 15

HBM Holdings Monthly Return: Issued Shares Edge Up 0.08% on Option Exercises; Public Float Maintained

Bulletin Express
·
Jul 07

HBM Holdings (SEHK:2142) Teams Up With Lonza, Is The Stock Already Fully Valued?

Simply Wall St.
·
Jul 04

Nona Biosciences and Lonza Enter Strategic Collaboration to Develop Best-in-class Single-domain Antibody-based Bbb-crossing Technology for CNS Diseases

THOMSON REUTERS
·
Jul 02

Shanghai Court Dismisses HBM Subsidiary's Patent Infringement Claim Against Biocytogen

MT Newswires Live
·
Jun 29

Harbour Biomed Appoints Lloyd Klickstein Scientific Advisor for Immunology

Reuters
·
Jun 29

HBM Holdings Annual Meeting: All Eight Resolutions Secure Strong Shareholder Support

Bulletin Express
·
Jun 25

HBM HOLDINGS-B Shares Surge on AI Drug Discovery Venture Announcement

Stock News
·
Jun 17

HBM Holdings and Baidu's Biotech Arm Forge AI Drug Discovery Alliance, Launching MegaStream TechBio

Stock News
·
Jun 15

HBM Holdings partners with BioMap to co-found AI drug R&D venture MegaStream TechBio

Reuters
·
Jun 15